Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R8TB
|
|||
| Former ID |
DIB000583
|
|||
| Drug Name |
ERA-923
|
|||
| Synonyms |
Pipendoxifene; UNII-TPC5Q8496G; 198480-55-6; CHEMBL44426; TPC5Q8496G; Pipendoxifene [INN]; ERA 923; AC1O5FKF; SCHEMBL134583; JICOGKJOQXTAIP-UHFFFAOYSA-N; ZINC602799; BDBM50099587; AKOS030631784; DB05414; 2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol; US8815934, No 97; US8815934, No 107; 2-(p-Hydroxyphenyl)-3-methyl-1-(p-(2-piperidinoethoxy)benzyl)indol-5-ol; 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Discontinued in Phase 2 | [1] | |
| Company |
Wyeth
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H32N2O3
|
|||
| Canonical SMILES |
CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
|
|||
| InChI |
1S/C29H32N2O3/c1-21-27-19-25(33)11-14-28(27)31(29(21)23-7-9-24(32)10-8-23)20-22-5-12-26(13-6-22)34-18-17-30-15-3-2-4-16-30/h5-14,19,32-33H,2-4,15-18,20H2,1H3
|
|||
| InChIKey |
JICOGKJOQXTAIP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 198480-55-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011640) | |||
| REF 2 | Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer. 2006 Sep;13(3):863-73. | |||
| REF 3 | Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem. 2001 May 24;44(11):1654-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.